Recent Finacing
Recent Raise
EuMentis develops clinical-stage and preclinical CNS therapeutics for ASD, Tourette syndrome, and TBI, advancing an uncompetitive fast-off NMDAR modulator (EM-113) and oral PDE10A inhibitor (EM-221).
Focus Areas
Total Raised
Funding round
See the team members at Eumentis Therapeutics.
